Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Most substance-abuse/diversion risk statements align with the provided label excerpts, but several other claims (notably dosage range, availability in IR/ER, patent/generics/legal-penalty assertions, and mechanism wording) are not supported by the provided prescribing information excerpts and cannot be verified against them.
Category Scores
Accurate Statements
Adderall is a prescription medication that combines amphetamine and dextroamphetamine.
Not fully assessable for 'prescription'/'combined amphetamine and dextroamphetamine' from provided excerpts, but active ingredients listed as mixed salts of amphetamine products (d-amphetamine and l-amphetamine salts) are consistent with containing amphetamine/dextroamphetamine components.
Adderall is primarily used to treat Attention Deficit Hyperactivity Disorder (ADHD).
SECTION 1 — INDICATIONS AND USAGE: indicated for treatment of ADHD and Narcolepsy.
Adderall is primarily used to treat narcolepsy.
SECTION 1 — INDICATIONS AND USAGE: indicated for treatment of ADHD and Narcolepsy.
Abuse/misuse/addiction risk (Adderall has high potential for abuse/misuse that can lead to substance use disorder including addiction; includes diversion, overdose/death risk, and need to assess/monitor).
SECTION 5 — WARNINGS (Abuse, Misuse, and Addiction) and DRUG ABUSE AND DEPENDENCE — Controlled Substance/Abuse (including overdose and death) and Dependence.
Obtaining Adderall without a valid prescription carries risks including addiction.
Label supports abuse/misuse leading to substance use disorder including addiction and that Adderall can be diverted for non-medical use; however the label does not address 'without a valid prescription' specifically.
Obtaining Adderall without a valid prescription carries risks including overdose.
SECTION 5 — WARNINGS and DRUG ABUSE AND DEPENDENCE — Abuse: misuse/abuse can result in overdose and death; increased risk with higher doses or unapproved methods of administration.
Obtaining Adderall without a valid prescription carries risks including serious cardiovascular side effects.
DRUG ABUSE AND DEPENDENCE — Abuse: misuse/abuse of amphetamines may cause increased heart rate and blood pressure, among other effects; provided excerpt supports cardiovascular effects in the context of misuse/abuse.
Unsupported Statements
Adderall works by affecting the balance of certain chemicals in the brain.
No pharmacology/mechanism content was provided in the supplied excerpts.
Adderall can improve focus.
No efficacy/clinical-study or outcome statements related to 'focus' were provided in the supplied excerpts.
Adderall can reduce impulsive behavior.
No clinical-outcome statements related to impulsivity were provided in the supplied excerpts.
Adderall is available in immediate-release and extended-release formulations.
No dosage-form/formulation information (IR vs ER) was provided in the supplied excerpts (only that label revision relates to Adderall immediate-release tablets).
Dosages of Adderall typically range from 5 mg to 60 mg per day.
No dosage/strength/dosing regimen content was provided in the supplied excerpts.
Obtaining Adderall without a valid prescription carries risks including receiving counterfeit medication.
No content in the provided excerpts addresses counterfeit drugs or counterfeit-specific risks.
Counterfeit Adderall may contain dangerous substances.
No counterfeit-specific content was provided.
Counterfeit Adderall may contain incorrect dosages.
No counterfeit-specific content was provided.
Illegally possessing and distributing prescription drugs can lead to severe legal consequences.
No legal/penalty information is present in the provided prescribing information excerpts.
The original patents for Adderall have long expired.
No patent history information is present in the provided prescribing information excerpts.
Generic versions of amphetamine and dextroamphetamine salts are widely available.
No market/generic availability statements are present in the provided prescribing information excerpts.
The existence of generics generally lowers the cost of the medication through legitimate pharmaceutical channels.
No cost/market access statements are present in the provided prescribing information excerpts.
Selling Adderall without a prescription is illegal.
No legal-statute information is present in the provided prescribing information excerpts.
Selling Adderall without a prescription is considered drug trafficking.
No legal classification/statute information is present in the provided prescribing information excerpts.
Penalties for selling Adderall without a prescription can include substantial fines.
No penalty/fining information is present in the provided prescribing information excerpts.
Penalties for selling Adderall without a prescription can include lengthy prison sentences.
No penalty/prison information is present in the provided prescribing information excerpts.
Penalties for selling Adderall without a prescription can include a criminal record.
No penalty/legal-record information is present in the provided prescribing information excerpts.
The severity of penalties for selling Adderall without a prescription depends on the quantity of the drug involved and the intent of the seller.
No legal-penalty decision criteria are present in the provided prescribing information excerpts.
Adderall is available in immediate-release and extended-release formulations.
Not supported/verified from the provided excerpts (which mention immediate-release tablets in context).
Contradictions
Important Omissions
When making abuse/misuse diversion risk statements, the label also recommends educating patients/families about risks and proper disposal of unused drug, advising safe storage (preferably locked), and instructing patients not to give Adderall to anyone else; these specific counseling/storage instructions were not included in the provided claims list.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Label-supported abuse/misuse/addiction and overdose/death risk statements were mostly aligned, but multiple unsupported claims (counterfeit-specific risks, dosage range, formulation availability, and mechanism/effect claims) reduce reliability; unsupported dosing/formulation content could be misused even if not directly medical-advice.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several claims are not supported by the provided prescribing-information excerpts, especially counterfeit drug details, dosing range (5–60 mg/day), IR vs ER availability, and mechanistic/clinical-effect statements.
Suggested Improvement
Restrict claims to the provided label-supported content: indications (ADHD and narcolepsy) and abuse/misuse/addiction/diversion/overdose-death risk, including the label's counseling and monitoring/storage recommendations; remove or qualify unsupported counterfeit, dosage, formulation, mechanism, and legal/patent/generic-market assertions.